The Asia Pacific Pyrogen Testing Market would witness market growth of 8.7% CAGR during the forecast period (2023-2030).
Companies are increasingly outsourcing these testing services to specialized testing laboratories. Outsourcing allows manufacturers to access state-of-the-art testing facilities and expertise without significant upfront investments in equipment and personnel. This trend is particularly evident among smaller companies looking to streamline their testing processes and focus on core competencies. Moreover, innovation remains at the forefront of the market, driving the development of new testing methodologies, instruments, and approaches.
Advanced spectroscopy techniques, including Raman spectroscopy and infrared spectroscopy, are being applied to this testing. These techniques provide detailed molecular information, enhancing the specificity and sensitivity of detection methods. Ongoing research efforts focus on developing novel in vitro assays for this testing. These assays aim to mimic the physiological response to pyrogens more accurately, providing reliable alternatives to traditional in vivo tests.
The pharmaceutical sector in India has experienced substantial growth in drug manufacturing activities. As the production of pharmaceuticals expands, there is a proportional rise in the demand for quality assurance measures, including this testing, to ensure that the manufactured drugs meet international safety and quality standards. As per the data from Invest India, the pharmaceutical sector in India currently holds a valuation of $50 billion. The pharmaceutical industry in India is projected to generate revenue of $65 billion by 2024, up from $130 billion by 2030. Hence, the rising pharmaceutical sector in the Asia Pacific will boost the demand for this testing in the region.
The China market dominated the Asia Pacific Pyrogen Testing Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $192.7 Million by 2030. The Japan market is registering a CAGR of 8% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 9.3% during (2023 - 2030).
Based on Product & Service, the market is segmented into Reagents & Kits, Services, and Instruments. Based on Test Type, the market is segmented into LAL Test, Rabbit Pyrogen Test, and Others. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Medical Device Companies, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Companies are increasingly outsourcing these testing services to specialized testing laboratories. Outsourcing allows manufacturers to access state-of-the-art testing facilities and expertise without significant upfront investments in equipment and personnel. This trend is particularly evident among smaller companies looking to streamline their testing processes and focus on core competencies. Moreover, innovation remains at the forefront of the market, driving the development of new testing methodologies, instruments, and approaches.
Advanced spectroscopy techniques, including Raman spectroscopy and infrared spectroscopy, are being applied to this testing. These techniques provide detailed molecular information, enhancing the specificity and sensitivity of detection methods. Ongoing research efforts focus on developing novel in vitro assays for this testing. These assays aim to mimic the physiological response to pyrogens more accurately, providing reliable alternatives to traditional in vivo tests.
The pharmaceutical sector in India has experienced substantial growth in drug manufacturing activities. As the production of pharmaceuticals expands, there is a proportional rise in the demand for quality assurance measures, including this testing, to ensure that the manufactured drugs meet international safety and quality standards. As per the data from Invest India, the pharmaceutical sector in India currently holds a valuation of $50 billion. The pharmaceutical industry in India is projected to generate revenue of $65 billion by 2024, up from $130 billion by 2030. Hence, the rising pharmaceutical sector in the Asia Pacific will boost the demand for this testing in the region.
The China market dominated the Asia Pacific Pyrogen Testing Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $192.7 Million by 2030. The Japan market is registering a CAGR of 8% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 9.3% during (2023 - 2030).
Based on Product & Service, the market is segmented into Reagents & Kits, Services, and Instruments. Based on Test Type, the market is segmented into LAL Test, Rabbit Pyrogen Test, and Others. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Medical Device Companies, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Merck KGaA
- Charles River Laboratories International, Inc.
- Genscript Biotech Corporation
- WuXi AppTec Co., Ltd.
- Lonza Group Ltd.
- Fujifilm Holdings Corporation
- Eurofins Scientific SE
- Thermo Fisher Scientific, Inc.
- Seikagaku Corp.
- InvivoGen SAS
Market Report Segmentation
By Product & Service- Reagents & Kits
- Services
- Instruments
- LAL Test
- Rabbit Pyrogen Test
- Others
- Pharmaceutical & Biotechnology Companies
- Medical Device Companies
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Pyrogen Testing Market, by Product & Service
Chapter 5. Asia Pacific Pyrogen Testing Market, by Test Type
Chapter 6. Asia Pacific Pyrogen Testing Market, by End User
Chapter 7. Asia Pacific Pyrogen Testing Market, by Country
Chapter 8. Company Profiles
Companies Mentioned
- Merck KGaA
- Charles River Laboratories International, Inc.
- Genscript Biotech Corporation
- WuXi AppTec Co., Ltd.
- Lonza Group Ltd.
- Fujifilm Holdings Corporation
- Eurofins Scientific SE
- Thermo Fisher Scientific, Inc.
- Seikagaku Corp.
- InvivoGen SAS
Methodology
LOADING...
